DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Sensipar (Cinacalcet Hydrochloride) - Published Studies

 
 



Sensipar Related Published Studies

Well-designed clinical trials related to Sensipar (Cinacalcet)

A novel dose regimen of cinacalcet in the treatment of severe hyperparathyroidism in hemodialysis patients. [2011.05]

The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. [2011.04]

Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. [2011.01]

Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. [2010.12]

Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. [2010.06]

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. [2010.01]

Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. [2009.12]

Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. [2009.03]

Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. [2009.01]

Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet. [2009]

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. [2008.11]

Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. [2008.10]

Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study. [2008.08]

Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. [2008.05.27]

An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. [2008.04]

Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. [2008.04]

The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. [2008.01]

Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. [2007.10]

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. [2007.09]

Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. [2007.02]

Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin. [2007]

Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. [2007]

First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. [2005.09]

Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. [2005.07]

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. [2005.03]

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. [2005.02]

Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. [2005.01]

Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. [2004.12]

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. [2004.04.08]

The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. [2003.12]

Well-designed clinical trials possibly related to Sensipar (Cinacalcet)

A pilot study of active vitamin D administration and insulin resistance in African American patients undergoing chronic hemodialysis. [2013]

The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. [2009.09]

[Chronic kidney disease (CKD) and bone. Control of CKD-MBD from the viewpoint of the medical cost] [2009.04]

Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants. [2009.01]

Modification of cardiovascular risk in hemodialysis patients: An evidence-based review. [2007.01]

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. [2003.03]

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. [2003.01]

The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. [2002.04]

Other research related to Sensipar (Cinacalcet)

Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. [2015]

A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet. [2014]

Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: results of a prospective randomized controlled study. [2013]

Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism. [2013]

MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. [2012]

Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. [2012]

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. [2012]

Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. [2011.12]

Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. [2011.11.28]

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. [2011.09.19]

Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. [2011.09]

Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride. [2011.09]

Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease. [2011.08]

Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. [2011.07.05]

Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism. [2011.07]

Novel electrochemiluminescence immunoassay exclusively for full-length parathyroid hormone during treatment with cinacalcet for secondary hyperparathyroidism. [2011.06]

Tertiary hyperparathyroidism resistant to cinacalcet treatment. [2011.06]

Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. [2011.06]

Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects. [2011.06]

Clinical utilization of cinacalcet in hypercalcemic conditions. [2011.04]

Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. [2011.04]

The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism. [2011.03.15]

[Use of cinacalcet in clinical practice for the treatment of secondary hyperparathyroidism: analysis of the Italian data of the ECHO study]. [2011.03]

Calcific uremic arteriolopathy treated with cinacalcet, paricalcitol, and autologous growth factors. [2011.03]

Cinacalcet in the treatment of persistent hyperparathyroidism after kidney transplantation. [2011.03]

Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study. [2011.03]

[Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery]. [2011.01]

Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study. [2011.01]

[German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)]. [2011.01]

Renal function in patients treated with cinacalcet for persistent hyperparathyroidism after kidney transplantation. [2011]

Effect of cinacalcet on renal electrolyte handling and systemic arterial blood pressure in kidney transplant patients with persistent hyperparathyroidism. [2011]

A novel dose regimen of cinacalcet in the treatment of severe hyperparathyroidism in hemodialysis patients. [2011]

Evaluation of cinacalcet HCl treatment after kidney transplantation. [2010.09]

Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. [2010.09]

Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. [2010.07]

Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. [2010.06]

Parathyroid gland ultrasound patterns and biochemical findings after one-year cinacalcet treatment for advanced secondary hyperparathyroidism. [2010.04]

[Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy] [2010.04]

Cinacalcet in the treatment of intractable hypercalcemia following two neck exploration surgeries for primary hyperparathyroidism. [2010.03]

The effects of discontinuing cinacalcet at the time of kidney transplantation. [2010.02]

Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient. [2010.02]

[Analysis of the efficacy and factors influencing the response of secondary hyperparathyroidism patients on hemodialysis to cinacalcet] [2010]

Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. [2010]

Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size. [2010]

Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. [2010]

Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. [2010]

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. [2010]

Does cinacalcet improve the prognosis of dialysis patients? [2009.10]

Clinical issues regarding cinacalcet hydrochloride in Japan. [2009.10]

Postoperative hypocalcemia after parathyroidectomy for renal hyperparathyroidism in the era of cinacalcet. [2009.09]

Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. [2009.09]

Cinacalcet-induced leukocytoclastic vasculitis. [2009.08]

Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. [2009.08]

[Multiple peritrochanteric and pubic calcifications in a young woman on hemodialysis with severe renal osteodystrophy successfully treated with sevelamer+cinacalcet+paracalcitol combination therapy] [2009.05]

[Cinacalcet in the treatment of secondary hyperparathyreoidism in a child with chronic kidney disease--case report] [2009.04]

[Chronic kidney disease (CKD) and bone. The clinical perspective of parathyroid interventional therapy for advanced secondary hyperparathyroidism in the era of cinacalcet HCl] [2009.04]

Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. [2009.03]

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. [2009.02]

Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients. [2009.02]

Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. [2009.02]

Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. [2009.01.30]

Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. [2008.12]

A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet. [2008.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017